This story originally ran on Oct. 6

Vermillion this week released top-line data from the intended use study for its peripheral artery disease biomarker test Vasclir.

The results demonstrated that the individual protein markers beta 2 microglobulin, cystatin C, and hsCRP are each expressed at statistically significant levels between PAD subjects and non-PAD subjects, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.